

# SCIENTIFIC REPORTS



OPEN

## CRF receptor 1 antagonism and brain distribution of active components contribute to the ameliorative effect of rikkunshito on stress-induced anorexia

Received: 16 September 2015

Accepted: 09 May 2016

Published: 08 June 2016


Sachiko Mogami<sup>1</sup>, Chiharu Sadakane<sup>1</sup>, Miwa Nahata<sup>1</sup>, Yasuharu Mizuhara<sup>1</sup>, Chihiro Yamada<sup>1</sup>, Tomohisa Hattori<sup>1</sup> & Hiroshi Takeda<sup>2,3</sup>

Rikkunshito (RKT), a Kampo medicine, has been reported to show an ameliorative effect on sustained hypophagia after novelty stress exposure in aged mice through serotonin 2C receptor (5-HT<sub>2C</sub>R) antagonism. We aimed to determine (1) whether the activation of anorexigenic neurons, corticotropin-releasing factor (CRF), and pro-opiomelanocortin (POMC) neurons, is involved in the initiation of hypophagia induced by novelty stress in aged mice; (2) whether the ameliorative effect of RKT is associated with CRF and POMC neurons and downstream signal transduction; and (3) the plasma and brain distribution of the active components of RKT. The administration of RKT or 5-HT<sub>2C</sub>R, CRF receptor 1 (CRFR1), and melanocortin-4 receptor antagonists significantly restored the decreased food intake observed in aged male C57BL/6 mice in the early stage after novelty stress exposure. Seven components of RKT exhibited antagonistic activity against CRFR1. Hesperetin and isoliquiritigenin, which showed antagonistic effects against both CRFR1 and 5-HT<sub>2C</sub>R, were distributed in the plasma and brain of male Sprague-Dawley rats after a single oral administration of RKT. In conclusion, the ameliorative effect of RKT in this model is assumed to be at least partly due to brain-distributed active components possessing 5-HT<sub>2C</sub>R and CRFR1 antagonistic activities.

Late-life anxiety and depression is a social problem in aging societies, and the recognition of this condition and adequate treatment are increasingly required<sup>1</sup>. Adverse life events are associated with the onset and persistence of depression<sup>2</sup>, which is characterized by feeding abnormalities (anorexia and bulimia). In particular, the co-occurrence of depression and anorexia may influence morbidity and progressive physical disability in the elderly<sup>3,4</sup>.

Japanese traditional (herbal) or “Kampo” medicines are standardized with regard to the quality and quantity of their ingredients and have been approved by the Japanese Ministry of Health and Welfare. At present, almost 90% of physicians in Japan use Kampo medicines in their daily practice, sometimes as the first choice for treatment<sup>5,6</sup>. Rikkunshito (RKT) is a Kampo medicine that is often prescribed for anorexia and upper gastrointestinal disorders<sup>7–9</sup>. In addition, several multicenter, double-blind, randomized placebo-controlled studies have been conducted to examine its effects<sup>10,11</sup>. Various non-clinical studies of RKT have also been performed and have demonstrated its ameliorative effects on hypophagia and gastrointestinal dysmotility<sup>12</sup>. We have previously shown that RKT improves the sustained decrease in food intake that occurs after novelty stress exposure in aged mice and that its effect are associated with serotonin 2C receptor (5-HT<sub>2C</sub>R) antagonism<sup>13,14</sup>. It has also been reported that several RKT components possess 5-HT<sub>2C</sub>R antagonistic activities *in vitro*<sup>13,15</sup>. However, the inhibitory activities of these components are assumed to be insufficient to explain the complete set of effects of RKT, indicating the involvement of another mechanism of action.

<sup>1</sup>Tsumura Research Laboratories, Tsumura & Co., Ibaraki 300-1192, Japan. <sup>2</sup>Pathophysiology and Therapeutics, Faculty of Pharmaceutical Sciences, Hokkaido University, Sapporo, Hokkaido 060-0812, Japan. <sup>3</sup>Hokkaido University Hospital Gastroenterological Medicine, Sapporo, Hokkaido 060-8648, Japan. Correspondence and requests for materials should be addressed to T.H. (email: hattori\_tomohisa@mail.tsumura.co.jp)



**Figure 1. Effect of RKT and a 5-HT<sub>2C</sub>R antagonist on novelty stress-induced hypophagia.** Aged male mice (77 ± 8 weeks old) were deprived of food overnight and orally administered the 5-HT<sub>2C</sub>R antagonist SB242084 (6 mg kg<sup>-1</sup>), RKT (1000 mg kg<sup>-1</sup>) or DW. Immediately after administration, the mice were exposed to novelty stress and their cumulative food intake was measured. The data are presented as the mean ± SEM (*n* = 5). \*,\*\*\**p* < 0.05, 0.001, respectively, vs. the stress group based on Steel's test at 1 h and Dunnett's test at 3 h. DW, distilled water; RKT, rikkunshito.

There is intimate interplay between 5-HT<sub>2C</sub>R and anorexigenic corticotropin-releasing factor (CRF) neurons. The administration of 5-HT<sub>2C</sub>R agonists leads to increased levels of stress hormones in the blood<sup>16</sup>. Moreover, CRF-containing neurons in the paraventricular nucleus of the hypothalamus (PVN) co-express 5-HT<sub>2C</sub>R mRNA<sup>17</sup>. Conversely, the CRF-induced decrease in orexigenic hormone secretion is restored by 5-HT<sub>2C</sub>R antagonism<sup>18</sup>, indicating that CRF and 5-HT<sub>2C</sub>R signals influence each other. Furthermore, it has been reported that 5-HT<sub>2C</sub>R is also expressed in anorexigenic pro-opiomelanocortin (POMC) neurons in the arcuate nucleus and that 5-HT<sub>2C</sub>R activation promotes α-melanocyte-stimulating hormone (α-MSH) production<sup>19–21</sup>. This production contributes to appetite suppression via melanocortin-4 receptor (MC4R) activation. However, it remains to be determined whether the ameliorative effects of RKT are associated with these anorexigenic neurons and downstream signal transduction. Furthermore, whether RKT components exert any effects on CRF receptors (CRFRs) or MC4R is unclear to date.


Various active components of RKT have been previously identified, and their 5-HT<sub>2C</sub>R antagonistic effects have been described<sup>13,15</sup>. Recently, the plasma levels of 32 RKT components were characterized in healthy volunteers after a single oral administration<sup>22</sup>. However, it is crucial to determine whether the active components of RKT penetrate the blood–brain barrier (BBB) if RKT exerts its effect on CRF and POMC neurons in the brain that are considered to be involved in the stress response. The brain distribution of RKT components in humans can only be estimated based on their distribution in the cerebrospinal fluid or determined through positron emission tomography. However, such analyses are difficult to perform for RKT because it contains various types of components.

The present study was conducted to determine 1) whether the activation of anorexigenic CRF or POMC neurons is involved in the initiation of hypophagia induced by novelty stress in aged mice; 2) whether the ameliorative effect of RKT is associated with anorexigenic CRF or POMC neurons and downstream signal transduction; and 3) the plasma and brain distributions of RKT active components.

## Results

**Effects of RKT and a 5-HT<sub>2C</sub>R antagonist on the decrease in cumulative food intake in aged male mice after novelty stress exposure under fasting conditions.** Cumulative food intake over 1 and 3 h was significantly decreased by novelty stress exposure in aged male mice (*p* = 0.025 and 0.0004, respectively), and this decrease was significantly restored by the oral administration of RKT (*p* = 0.025 and 0.023, respectively) or the 5-HT<sub>2C</sub>R antagonist SB242084 (*p* = 0.025 and 0.013, respectively) at 1 and 3 h after novelty stress exposure (Fig. 1).

**Effects of CRFR1/2 or MC4R antagonists on the decrease in cumulative food intake in aged male mice after novelty stress exposure under fasting conditions.** Intracerebroventricular (ICV) administration of the CRFR1 antagonists NBI27914 significantly ameliorated the decrease in food intake that occurred after novelty stress exposure in aged male mice at 3 and 6 h after stress exposure (*p* = 0.005 and *p* = 0.074, respectively). In contrast, the CRFR2 antagonist astressin 2B showed a negligible effect at 3 and 6 h after novelty stress exposure but tended to partially restore the decrease in food intake after 24 h (*p* = 0.051). ICV administration of the MC4R antagonist HS014 also significantly restored food intake at 3 and 6 h (*p* = 0.028 and *p* = 0.009, respectively) after novelty stress exposure (Fig. 2).



**Figure 2. Effects of intracerebroventricular (ICV) administration of CRFR antagonists and an MC4R antagonist on novelty stress-induced hypophagia.** Aged male mice ( $77 \pm 8$  weeks old) were deprived of food overnight, and a CRFR1 antagonist (NBI27914,  $10 \mu\text{g}$  per mouse), a CRFR2 antagonist (astressin 2B,  $10 \mu\text{g}$  per mouse), an MC4R antagonist (HS014,  $0.15 \mu\text{g}$  per mouse) or sterilized physiological saline was administered via ICV injection. Immediately after administration, the mice were exposed to novelty stress and their cumulative food intake was measured. The data are presented as the mean  $\pm$  SEM ( $n = 5$ , except for the stress group at 6 h;  $n = 4$ ). \*\*\*,\*\*,\* $p < 0.05$ , 0.01, 0.001, respectively, vs. the stress group based on Dunnett's test at 3 and 6 h and Steel's test at 24 h.

Components	Crude drug	IC <sub>50</sub> ( $\mu\text{mol/L}$ )	K <sub>B</sub> ( $\mu\text{mol/L}$ )
Nobiletin	Citri Unshiu Pericarpium	15	0.36
Tangeretin	Citri Unshiu Pericarpium	60	1.5
Hesperetin	Citri Unshiu Pericarpium	130	45
Isoliquiritigenin	Glycyrrhizae Radix	28	0.67
Glycoumarin	Glycyrrhizae Radix	52	1.3
Glycyrrhetic acid	Glycyrrhizae Radix	14	0.35
[8]-Shogaol	Zingiberis Rhizoma	74	1.8

**Table 1. Antagonistic effects of rikkunshito components against CRFR1.**

Components	Crude drug	IC <sub>50</sub> ( $\mu\text{mol/L}$ )
Hesperetin	Citri Unshiu Pericarpium	48.2 <sup>*</sup>
Isoliquiritigenin	Glycyrrhizae Radix	5.5 <sup>*</sup>
Glycoumarin	Glycyrrhizae Radix	7.7 <sup>*</sup>
[8]-Shogaol	Zingiberis Rhizoma	36.9 <sup>*</sup>


**Table 2. Antagonistic effects of rikkunshito components against 5-HT<sub>2C</sub>R.** \*IC<sub>50</sub> ( $\mu\text{mol/L}$ ) values for the cell function assay have been previously reported by Nahata *et al.*<sup>13</sup>.

**Antagonistic effect of RKT components against CRFR1.** Among the 36 RKT components assayed, glycoumarin, nobiletin, tangeretin, isoliquiritigenin, [8]-shogaol, glycyrrhetic acid, and hesperetin exhibited inhibitory effects on the ovine CRF-induced increase in cAMP levels in CRFR1-transfected cells. The corresponding IC<sub>50</sub> and K<sub>B</sub> values are provided in Table 1. The same 36 RKT components showed low binding affinities for MC4R (data not shown).

**Determination of plasma concentrations of RKT components after a single oral administration of RKT in rats.** The plasma levels of RKT components that demonstrated CRFR1 (Table 1) or 5-HT<sub>2C</sub>R antagonistic effects (Table 2)<sup>13</sup> were investigated after a single oral administration of RKT at a dose of  $1000 \text{ mg kg}^{-1}$  in rats (Table 3). The ameliorative effect of RKT on hypophagia in young mice has been previously reported in several studies<sup>18,23</sup>. Therefore, we investigated the distribution of RKT components in young animals in the present study. We used rats to obtain a sufficient amount of plasma for our investigation. Because isoliquiritigenin and liquiritigenin have been reported to be chemically interchangeable<sup>24,25</sup>, we also examined the plasma levels of liquiritigenin and its glycoside forms that are present in RKT at high levels<sup>22</sup>. The chemical structures of hesperetin and its glycoside (hesperidin) are shown in Fig. 3A; those of liquiritigenin and its glycosides (liquiritin

Compound	Crude drug	Plasma concentration (ng/ mL)		
		0.5 h	1 h	2 h
Nobiletin	Citri Unshiu Pericarpium	0.492 ± 0.190	0.127 ± 0.0306	0.0225 ± 0.000285
Tangeretin	Citri Unshiu Pericarpium	<0.020	<0.020	<0.020
Hesperetin	Citri Unshiu Pericarpium	0.192 ± 0.192	<0.100	<0.100
liquiritin apioside	Glycyrrhizae Radix	2.60 ± 0.699	1.73 ± 0.0985	0.913 ± 0.359
liquiritin	Glycyrrhizae Radix	2.84 ± 0.968	1.11 ± 0.0748	0.309 ± 0.213
Isoliquiritigenin	Glycyrrhizae Radix	0.392 ± 0.000667	0.267 ± 0.0361	0.174 ± 0.0347
Glycyrrhetic acid	Glycyrrhizae Radix	2.00 ± 1.68	0.396 ± 0.202	17.7 ± 16.6
Glycy coumarin	Glycyrrhizae Radix	<0.020	<0.020	<0.020
[8]-Shogaol	Zingiberis Rhizoma	<0.100	<0.100	<0.100

**Table 3.** Plasma concentrations after the oral administration of rikkunshito at 1000 mg kg<sup>-1</sup> in rats.



**Figure 3.** Chemical structures of rikkunshito components. (A) Hesperetin and its glycoside. (B) Liquiritigenin and its glycosides. (C) Isoliquiritigenin and its glycosides. Api, apiose; Glc, glucose.


and liquiritin apioside) are shown in Fig. 3B; and those of isoliquiritigenin and its glycosides (isoliquiritin and isoliquiritin apioside) are shown in Fig. 3C. Among these components, the plasma concentration of liquiritin was highest with  $C_{max}$  being observed at 0.5 h after administration, followed by liquiritin apioside. Hesperetin, glycy coumarin and isoliquiritigenin were detected at low levels in plasma. Tangeretin, glycy coumarin and [8]-shogaol were below the detection limits.

**Brain distribution of hesperetin and isoliquiritigenin.** Among the RKT components that were detected in plasma, we chose to determine the levels of hesperetin and isoliquiritigenin in the brain because they exhibited antagonistic effects on both CRFR1 and 5-HT<sub>2C</sub>R. Although the antagonistic activity of hesperetin was low, hesperidin showed the highest level in the RKT extract among the components of RKT<sup>22,26</sup>. We collected brain samples at 3 h after oral administration because RKT was most effective at 3 h, as shown in Fig. 1. Typical chromatograms of the authentic standards, blank, and brain sample are shown in Supplementary Figs S1 and S2. Hesperetin was detected in rat brains after the oral administration of RKT (1000 mg kg<sup>-1</sup>) or hesperidin (5 and 15 mg kg<sup>-1</sup>) (Fig. 4A). Isoliquiritigenin was also detected after the oral administration of RKT or isoliquiritigenin itself at 5 and 15 mg kg<sup>-1</sup> (Fig. 4B). Furthermore, when we administered liquiritin at 50 mg kg<sup>-1</sup>, a comparable amount of isoliquiritigenin was detected in the brain (Fig. 4B).


## Discussion

In this study, we showed that 1) several components of RKT exhibited antagonistic activities against CRFR1; 2) hesperetin (Citri Unshiu Pericarpium-derived) and isoliquiritigenin (Glycyrrhizae Radix-derived), which are major active components of RKT that possess both CRFR1 and 5-HT<sub>2C</sub>R antagonistic activities, were distributed in the plasma and brain after a single oral administration of RKT; and 3) CRFR1 and MC4R antagonists, in addition to RKT and a 5-HT<sub>2C</sub>R antagonist, restored the initial decrease in food intake that occurred after novelty stress exposure in aged mice. Based on these results, we conclude that the ameliorative effect of RKT in this model is at least partly attributable to brain-distributed active components possessing CRFR1 and 5-HT<sub>2C</sub>R antagonistic activities.

We have previously shown that RKT ameliorates the occurrence of prolonged hypophagia after novelty stress exposure in aged mice<sup>13,14</sup>. In the present study, we investigated the effect of RKT at 1 and 3 h after novelty stress



**Figure 4. Brain levels of hesperetin and isoliquiritigenin after the oral administration of rikkunshito (RKT).** (A) Hesperetin levels in the whole brain were determined in rats 3 h after a single oral administration of RKT (1000 mg kg<sup>-1</sup>,  $n = 4$ ) and hesperidin (glycoside form of hesperetin, 5 and 15 mg kg<sup>-1</sup>,  $n = 4, 5$ ). (B) Isoliquiritigenin levels in the whole brain were measured in rats 3 h after a single oral administration of RKT (1000 mg kg<sup>-1</sup>,  $n = 5$ ), isoliquiritigenin (5 and 15 mg kg<sup>-1</sup>,  $n = 5$ ) or liquiritin (50 mg kg<sup>-1</sup>,  $n = 3$ ). The data are presented as the mean  $\pm$  SEM.



**Figure 5. A hypothesis to explain the ameliorative effect of rikkunshito on novelty stress-induced anorexia.** Activation of 5-HT<sub>2c</sub>R induces CRF neuron and POMC neuron activation and causes appetite loss after novelty stress exposure in aged male mice. RKT is assumed to exert its ameliorative effect via 5-HT<sub>2c</sub>R antagonism and CRFR1 antagonism in the brain. CRF, corticotropin-releasing factor; CRFR1, CRF type-1 receptor; 5-HT, serotonin; 5-HT<sub>2c</sub>R, 5-HT<sub>2c</sub> receptor; MC4R, melanocortin-4 receptor; POMC, pro-opiomelanocortin; PVN, paraventricular nucleus; ARC, arcuate nucleus; VMH, ventromedial hypothalamic nucleus; TMN, tuberomammillary nucleus.

exposure because we considered it important to investigate the effects in early stages to clarify the involvement of various neurotransmitters in the initiation of hypophagia after stress exposure in aged mice. A marked decrease in food intake was restored by the oral administration of RKT and a 5-HT<sub>2c</sub>R antagonist 1 h after novelty stress exposure in this study. This indicates that RKT and 5-HT<sub>2c</sub>R antagonists exert ameliorative effects, not only in the prolonged stage, but also in the early stage after novelty stress exposure in aged mice.

CRF and 5-HT play significant roles in the stress response and the regulation of feeding behaviors. Multiple lines of evidence indicate that there is a positive correlation between 5-HT<sub>2c</sub>R and CRF neuron activation. CRF-containing neurons in the PVN have been reported to be consistently depolarized in the presence of a high-affinity 5-HT<sub>2c</sub>R agonist<sup>17</sup> and CRF neurons activation in response to an antigenic stimulus was blunted in 5-HT<sub>2c</sub>R knockout mice<sup>27</sup>. CRF neuron activation during stress causes suppression of feeding behavior<sup>28,29</sup>. We investigated the effect of CRFR antagonists on novelty stress-induced hypophagia in aged male mice and found that ICV administration of CRFR1 antagonists, but not CRFR2 antagonists, inhibited the initial decrease in food intake. These results indicate that the activation of 5-HT<sub>2c</sub>R-CRF neuron-CRFR1 is involved in the initiation of hypophagia after novelty stress exposure in aged mice. Additionally, the activation of 5-HT<sub>2c</sub>R-CRF



neuron-CRFR2 may be partly involved in sustained hypophagia, as the CRFR2 antagonist demonstrated a partial ameliorative effect only at 24 h after stress exposure.

In the present study, we showed that ICV administration of an MC4R antagonist also inhibited the initial decrease in food intake induced by novelty stress exposure in aged mice. These results suggest that CRFR1 and MC4R activation resulting from anorexigenic CRF and POMC neuron activation is involved in the initiation of hypophagia induced by novelty stress exposure in aged mice (Fig. 5).

In the present study, we found that seven components of RKT showed antagonistic effects on CRFR1 (Table 1). To the best of our knowledge, this study is the first to report the antagonistic activities of these components against CRFR1. The same 36 RKT components showed low binding affinities for MC4R. Therefore, we assumed that the ameliorative effect of RKT was attributable to CRFR1 antagonism in addition to the 5-HT<sub>2C</sub>R antagonistic effect (Fig. 5).

In order to test our hypothesis that the antagonism of central CRFR1 and 5-HT<sub>2C</sub>R is involved in the ameliorative effect of RKT, we first confirmed that the RKT components possessing either CRFR1 or 5-HT<sub>2C</sub>R antagonistic activity were distributed in plasma. We also confirmed the brain distribution of hesperetin and isoliquiritigenin, which are components that possess both CRFR1 and 5-HT<sub>2C</sub>R antagonistic activities, after oral administration of RKT. Isoliquiritigenin has been reported to show an ameliorative effect on hypophagia after novelty stress in young mice<sup>18</sup>. Additionally, both isoliquiritigenin and hesperidin (the glycoside form of hesperetin) have also been observed to improve cisplatin-induced hypophagia in rats via 5-HT<sub>2C</sub>R antagonism<sup>15,30</sup>. Therefore, the brain distribution of these compounds after oral administration of RKT suggests that these components may exert their antagonistic effects on CRFR1 and 5-HT<sub>2C</sub>R in the brain and that they partially contribute to the ameliorative effect of RKT on hypophagia after novelty stress exposure.

In the present study, we detected isoliquiritigenin in brain tissue after the oral administration of RKT (1000 mg kg<sup>-1</sup>), and the levels in the brain were comparable to those observed after the oral administration of isoliquiritigenin itself at a dose of 5 mg kg<sup>-1</sup>. This level was much higher than expected, as isoliquiritigenin has been estimated to occur at approximately 0.019 mg per 1000 mg of RKT water extract<sup>22</sup>. Two types of its glycoside forms (isoliquiritin and isoliquiritin apioside) have been reported to occur at approximately 10 times the level of isoliquiritigenin itself in RKT<sup>26,22</sup>. Moreover, liquiritin and liquiritin apioside (glycoside form of liquiritigenin) have been reported to occur at 70–80 times the level of isoliquiritigenin in RKT<sup>22</sup>. As we detected isoliquiritigenin in the brain after liquiritin administration, a portion of the liquiritin and liquiritin apioside present in RKT may have become hydrolyzed and isomerized and been distributed in the brain as isoliquiritigenin.

The levels of hesperetin and isoliquiritigenin in the brain after oral administration of RKT may be insufficient relative to their  $K_B$  values to exert any pharmacological effect against CRFR1 and 5-HT<sub>2C</sub>R (almost one magnitude lower in the case of isoliquiritigenin). This implies that hesperetin and isoliquiritigenin alone are not sufficient to fully account for the effects of RKT. In the present study, we only measured the brain levels of two representative active components that possess both CRFR1 and 5-HT<sub>2C</sub>R antagonistic activities. Additionally, we showed that there are several other components that possess CRFR1 antagonistic effects *in vitro*, suggesting that these components might also exert antagonistic activities *in vivo*, although we did not investigate the brain distribution in this study. One such component is glycycomarin, which has been reported to ameliorate hypophagia after novelty stress exposure in young mice<sup>18</sup>. We also confirmed the *in vivo* effect of glycyrrhizin, the glycoside form of glycyrrhetic acid. Glycyrrhetic acid was shown to possess the highest *in vitro* CRFR1 antagonistic activity among the components evaluated in the present study and to exhibit no antagonistic activity against 5-HT<sub>2C</sub>R. Glycyrrhizin administration significantly restored the decreased food intake observed after novelty stress exposure in young mice (Supplementary Fig. S3). The extensive distribution of glycyrrhetic acid in the brain after an oral administration of yokukansan extract containing Glycyrrhizae Radix<sup>31</sup> suggests that glycyrrhetic acid is distributed at high levels after RKT administration. Therefore, these additional components possessing CRFR1 antagonistic activity may also have contributed to the ameliorative effect of RKT on hypophagia. Because CRFR1 antagonistic effects were detected in the present study, it will be necessary to investigate of contribution of nobiletin and tangeretin to the effects of RKT and their specific brain distribution in further studies, as they have been reported to be distributed in the brain *in vivo*<sup>32–34</sup>. Moreover, we only investigated 36 components of RKT in this study, and there may be other components that possess greater antagonistic activities against 5-HT<sub>2C</sub>R, CRFR1 or MC4R and that are distributed in the brain at higher levels. A non-targeted analysis to conduct a search for other active components will be necessary in further studies. In addition, there is a possibility that a combination of various active components that show multiple mechanisms of action may exert enhanced effects relative to the effect of a single component with a single target.

In the present study, we demonstrated the ameliorative effect of RKT in aged mice. Because the BBB in aged animals is reported to be more permeable than in younger animals<sup>35,36</sup>, greater amounts of active components may be distributed in the brains of aged animals than in younger animals. Further precise pharmacokinetic studies of RKT components in aged animals are required to examine those differences.

In conclusion, we demonstrated that the initiation of novelty stress-induced anorexia in aged mice is due to 5-HT<sub>2C</sub>R and CRFR1/MC4R activation. Our results also indicate that brain distributed components of RKT possessing CRFR1 and 5-HT<sub>2C</sub>R antagonistic activities may be partly involved in its ameliorative effect in this model. However, further investigation of other active components or combinations of these components is required to fully understand the effects of RKT.

## Materials and Methods

**Animals.** Male C57BL/6 mice at 77 ± 8 weeks of age and 6- to 7-week-old male Sprague Dawley rats were purchased from Charles River Laboratories Japan (Tokyo, Japan). We used mice before the onset of ageing cachexia. Before the experiments, five mice per cage or four to five rats per cage were acclimated in a temperature and humidity-controlled room under a 12-h light–dark cycle with free access to food and water. This study was

approved by and conducted according to the guidelines of the experimental animal ethics committees of Tsumura & Co. (Ibaraki, Japan, approved protocol No.: 11–134, 11–135, 12–113, 12–135).

**Rikkunshito.** RKT (Tsumura & Co.) was obtained by spray drying a hot water extract of a mixture of eight crude drugs: *Atractylodis lanceae* rhizoma (4.0 g), *Ginseng radix* (4.0 g), *Pinelliae tuber* (4.0 g), *Poria* (4.0 g), *Zizyphi fructus* (2.0 g), *Citri Unshiu Pericarpium* (2.0 g), *Glycyrrhizae radix* (1.0 g) and *Zingiberis rhizoma* (0.5 g). The major active components in 1 g of ‘Tsumura rikkunshito extract granules for prescription’ (1 g contains 0.53 g of the spray-dried hot water extract and pharmaceutical excipients) from a specific lot have been reported to be hesperidin, 3750 µg; glycyrrhizin, 1370 µg; narirutin, 932 µg; liquiritin, 801 µg; liquiritin apioside, 697 µg; isoliquiritin, 101 µg; isoliquiritin apioside, 85.2 µg; liquiritigenin, 79.8 µg; pachymic acid, 67.5 µg; atractylodin, 56.3 µg; heptamethoxyflavone, 23.4 µg; nobletin, 17.4 µg; isoliquiritigenin, 9.85 µg; naringenin, 3.95 µg and glycyrrhetic acid, 1.84 µg in a certain lot<sup>22</sup>.

**Exposure to novelty stress.** The novelty stress-induced hypophagia test can be used to evaluate the degree of anxiety or depression by evaluating the suppression of food intake after exposure to a novel environment<sup>37</sup>. Testing was performed as previously described<sup>13</sup>. Group-housed mice (five mice per cage) were suddenly transferred to separate cages (one mouse per cage) after overnight fasting. Control mice were housed in separate cages for 7 days before the beginning of the experiments. Provisional food intake by the group-housed mice was calculated to ensure that no differences were observed between the group-housed and control mice<sup>13</sup>.

**Effects of tested drugs on anorexia induced by novelty stress exposure in aged male mice.** The selective 5-HT<sub>2C</sub>R antagonist, SB242084 (6 mg kg<sup>-1</sup><sup>38,39</sup>; Sigma–Aldrich, St. Louis, MO, USA) and RKT (1000 mg kg<sup>-1</sup>) suspended in distilled water were orally administered to overnight fasted mice immediately after they were isolated ( $n = 5$ ). The administered dose of RKT is approximately equivalent to a typical clinical dose when converted based on body surface area (as recommended by the FDA) and this dose has previously been reported to show ameliorative effects in a mouse model of anorexia<sup>13,14,40,41</sup>. Cumulative food intake was determined at 1, 3 and 6 h after stress exposure. We previously confirmed that oral administration of SB242084 (6 mg kg<sup>-1</sup>) and RKT (1000 mg kg<sup>-1</sup>) to unstressed-young or aged mice does not affect food intake<sup>13</sup>.

To investigate the involvement of CRFR and MC4R on decreased food intake, the CRFR1 antagonist, NBI27914 (Sigma–Aldrich, 10 µg mouse<sup>-1</sup><sup>18,42</sup>), the CRFR2 antagonist astressin 2B (Sigma–Aldrich, 10 µg mouse<sup>-1</sup><sup>43,18</sup>) and the MC4R antagonist HS014 (Sigma–Aldrich, 0.15 µg mouse<sup>-1</sup><sup>44</sup>) were dissolved in physiological saline and administered via ICV injection immediately after novelty stress exposure, and food intake was subsequently measured. ICV administration was performed according to the method reported by Haley and McCormick<sup>45</sup>, with a slight modification. A 26-gauge stainless-steel needle attached to PE-10 tubing fitted to a 10-µL microsyringe was inserted into the brain (2.6 mm below the surface of the skull, 1.0 mm lateral and 0.5 mm anterior to the bregma) of lightly held mice. The injections were performed without anesthesia to avoid any short-time effects of anesthesia on food intake. An injection volume of 5 µL was administered over 30 s. Mice that showed visible bleeding or abnormal behaviors following ICV administration were excluded from the analysis because of the inadequacy of the administration procedure. Direct ICV administration was performed by a skilled individual who have confirmed the location of ICV injection through dye infusions with a success rate of 97%.

**In vitro functional assay of CRFR1 antagonistic activity of RKT components.** Evaluation of the antagonistic activity of various compounds against human CRFR1 in transfected CHO cells was performed at Cerep (Paris, France) by measuring the effects of the compounds on agonist-induced cAMP production via the HTRF detection method, as previously reported<sup>46</sup>. Briefly, the cells were pre-incubated in the presence of the test compound for 5 min at room temperature, and the reference agonist ovine CRF was added (10 nmol L<sup>-1</sup>), followed by 30 min of incubation at 37 °C. The cells were then lysed, and the fluorescence acceptor (D2-labelled cAMP) and fluorescence donor (anti-cAMP antibody labelled with europium cryptate) were added. After 60 min at room temperature, fluorescence transfer was measured ( $\lambda_{ex} = 337$  nm and  $\lambda_{em} = 620$  and 665 nm), and the cAMP concentration was determined by dividing the signal measured at 665 nm by that measured at 620 nm (ratio). The results are expressed as the percent inhibition of the control response to the reference agonist. A concentration–response curve was generated to calculate IC<sub>50</sub> values. The apparent dissociation constants ( $K_B$ ) were calculated using the modified Cheng-Prusoff equation ( $K_B = IC_{50}/(1 + (A/EC_{50A}))$ ), where  $A$  = the concentration of the reference agonist in the assay and  $EC_{50A}$  = the  $EC_{50}$  value of the reference agonist).

**Binding assay of RKT components with MC4R receptors.** Evaluation of the binding activity at human MC4R in transfected HEK-293 cells was performed at Ricerca Biosciences, LLC (Taipei, Taiwan) as previously reported<sup>47,48</sup>. Briefly, transfected cells were incubated for 2 h at 37 °C with 0.05 ml of binding buffer in each well, which also contained 0.02 nM [<sup>125</sup>I] NDP- $\alpha$ -MSH and a 100 µM concentration of the test compounds. All assays were performed in duplicate. After incubation, the cells were washed and detached from the plates, and radioactivity was counted.

**Determination of plasma levels of active components after the oral administration of RKT in rats.** Rats fasted overnight were orally administered 1000 mg kg<sup>-1</sup> of RKT and decapitated at 30, 60 and 120 min to collect blood samples ( $n = 3$ ). The blood was also collected from untreated rats as a control ( $n = 3$ ). Blood samples were heparinized and centrifuged at 3000 rpm for 10 min. Plasma samples were collected and stored at –80 °C until use. Determination of the plasma concentrations of the active components was performed by Sumika Chemical Analysis Service Ltd. (Osaka, Japan), as previously reported<sup>22</sup>. The method is summarized in the Supplementary Method.

**Brain distributions of hesperetin and isoliquiritigenin after the oral administration of RKT or its components in rats.** Rats were orally administered RKT (1000 mg kg<sup>-1</sup>), hesperidin (5, 15 mg kg<sup>-1</sup>), isoliquiritigenin (5, 15 mg kg<sup>-1</sup>) and liquiritin (50 mg kg<sup>-1</sup>) and decapitated 3 h after administration. The brain (the cerebrum except for the cerebellum, medulla oblongata and olfactory bulb) was collected and immediately frozen and stored at -20 °C until use. The brain was homogenized after adding 3 volumes (w/w) of distilled water.

For the preparation of calibration standards, each standard substance and 3-hydroxy chalcone (used as the internal standard [IS]) were separately dissolved in methanol to prepare standard stock solutions (100 µg ml<sup>-1</sup>). After mixing 0.1 ml of each standard stock solution except for the IS solution, the mixed solution was diluted with 50% acetonitrile to a final volume of 10 ml, which was the standard stock solution A (1 µg ml<sup>-1</sup>). Standard working solutions at concentrations ranging from 1 to 100 ng ml<sup>-1</sup> were prepared by further diluting standard stock solution A and adding IS solution (0.1 ml). The concentrations of the standard working solutions used for calibration curve matching of the matrix were 1, 5, 10, 50 and 100 ng ml<sup>-1</sup>. All of the stock solutions and working solutions were stored at -20 °C.

For isoliquiritigenin measurements, brain samples and calibration standards were extracted using ice cold MeOH/MeCN (1/1, v/v). Next, 400 µl of acetonitrile and 10 µl of IS solution were added to the samples and calibration standards. The samples were subsequently mixed for 3 min and centrifuged at 10,000 rpm for 5 min. The supernatant was transferred to a clear test tube and evaporated to dryness under a gradual nitrogen flow at 37 °C. The dried residue was reconstituted in 200 µl of 0.1% TFA containing 20% MeCN. A 50-µl aliquot of the solution was then injected into the HPLC system for analysis. For measurements of hesperetin, 10 µl of IS solution was added to the samples and calibration standards. The brain samples and calibration standards were then deproteinized with ice-cold trichloroacetic acid, followed by mixing for 3 min and centrifugation at 10000 rpm for 5 min. Finally, 50 µl of the supernatant was injected into the HPLC system for analysis.

For liquid chromatography, an LA-10ADvp system (Shimadzu) was used for solvent and sample delivery. A Symmetry C18 column (100 × 4.6 mm I.D., 3-µm particle size; Waters, Milford, MA) was employed to separate each analyte at 40 °C. The mobile phase consisted of solution A (0.1% TFA, v/v) and solution B (acetonitrile), and a gradient of solution B (10%, 0–5 min; 70%, 20 min; 70%, 25 min; and 10%, 25.1–30 min; v/v) at a flow rate of 0.9 ml/min was used during the analysis. The detection wavelengths were UV 285 nm for hesperetin and 369 nm for isoliquiritigenin.

**Statistical analyses.** Statistical analyses of mean values were performed with Dunnett's test or Steel's test vs. the stress group after applying Bartlett's test using StatLight 2000(C) (Yukms Co. Ltd.). The data are presented as the mean ± standard error for each group, and  $p < 0.05$  was considered to indicate statistical significance.

## References

1. Diefenbach, G. J. & Goethe, J. Clinical interventions for late-life anxious depression. *Clin Interv Aging* **1**, 41–50 (2006).
2. Paykel, E. S. Life events, social support and depression. *Acta Psychiatr Scand Suppl* **377**, 50–58 (1994).
3. Rowe, J. W. & Kahn, R. L. Human aging: usual and successful. *Science* **237**, 143–149 (1987).
4. Seeman, T. E. & Robbins, R. J. Aging and hypothalamic-pituitary-adrenal response to challenge in humans. *Endocr Rev* **15**, 233–260 (1994).
5. Moschik, E. C., Mercado, C., Yoshino, T., Matsuura, K. & Watanabe, K. Usage and attitudes of physicians in Japan concerning traditional Japanese medicine (kampo medicine): a descriptive evaluation of a representative questionnaire-based survey. *Evid Based Complement Alternat Med* **2012**, 139818 (2012).
6. Ito, A., Munakata, K., Imazu, Y. & Watanabe, K. First nationwide attitude survey of Japanese physicians on the use of traditional Japanese medicine (kampo) in cancer treatment. *Evid Based Complement Alternat Med* **2012**, 957082 (2012).
7. Suzuki, H., Inadomi, J. M. & Hibi, T. Japanese herbal medicine in functional gastrointestinal disorders. *Neurogastroenterol Motil* **21**, 688–696 (2009).
8. Tominaga, K. & Arakawa, T. Kampo medicines for gastrointestinal tract disorders: a review of basic science and clinical evidence and their future application. *J Gastroenterol* **48**, 452–462 (2013).
9. Oka, T. *et al.* Effects of Kampo on functional gastrointestinal disorders. *Biopsychosoc Med* **8**, 5 (2014).
10. Suzuki, H. *et al.* Randomized clinical trial: rikkunshito in the treatment of functional dyspepsia—a multicenter, double-blind, randomized, placebo-controlled study. *Neurogastroenterol Motil* **26**, 950–961 (2014).
11. Tominaga, K. *et al.* A randomized, placebo-controlled, double-blind clinical trial of rikkunshito for patients with non-erosive reflux disease refractory to proton-pump inhibitor: the G-PRIDE study. *J Gastroenterol* **49**, 1392–1405 (2014).
12. Mogami, S. & Hattori, T. Beneficial effects of rikkunshito, a Japanese kampo medicine, on gastrointestinal dysfunction and anorexia in combination with Western drug: a systematic review. *Evid Based Complement Alternat Med* **2014**, 519035 (2014).
13. Nahata, M. *et al.* Serotonin 2C receptor antagonism ameliorates novelty-induced hypophagia in aged mice. *Psychoneuroendocrinology* **38**, 2051–2064 (2013).
14. Yamada, C. *et al.* Serotonin 2C receptor contributes to gender differences in stress-induced hypophagia in aged mice. *Psychoneuroendocrinology* **55C**, 81–93 (2015).
15. Takeda, H. *et al.* Rikkunshito, an herbal medicine, suppresses cisplatin-induced anorexia in rats via 5-HT<sub>2</sub> receptor antagonism. *Gastroenterology* **134**, 2004–2013 (2008).
16. Hemrick-Luecke, S. K. & Evans, D. C. Comparison of the potency of MDL 100,907 and SB 242084 in blocking the serotonin (5-HT) (2) receptor agonist-induced increases in rat serum corticosterone concentrations: evidence for 5-HT(2A) receptor mediation of the HPA axis. *Neuropharmacology* **42**, 162–169 (2002).
17. Heisler, L. K. *et al.* Serotonin activates the hypothalamic-pituitary-adrenal axis via serotonin 2C receptor stimulation. *J Neurosci* **27**, 6956–6964 (2007).
18. Saegusa, Y. *et al.* Decreased plasma ghrelin contributes to anorexia following novelty stress. *Am J Physiol Endocrinol Metab* **301**, E685–696 (2011).
19. Heisler, L. K. *et al.* Activation of central melanocortin pathways by fenfluramine. *Science* **297**, 609–611 (2002).
20. Heisler, L. K. *et al.* Serotonin reciprocally regulates melanocortin neurons to modulate food intake. *Neuron* **51**, 239–249 (2006).
21. Lam, D. D. *et al.* Serotonin 5-HT<sub>2C</sub> receptor agonist promotes hypophagia via downstream activation of melanocortin 4 receptors. *Endocrinology* **149**, 1323–1328 (2008).



22. Kitagawa, H. *et al.* Pharmacokinetic Profiles of Active Ingredients and Its Metabolites Derived from Rikkunshito, a Ghrelin Enhancer, in Healthy Japanese Volunteers: A Cross-Over, Randomized Study. *PLoS One* **10**, e0133159 (2015).
23. Yamada, C. *et al.* Rikkunshito, a Japanese kampo medicine, ameliorates decreased feeding behavior via ghrelin and serotonin 2B receptor signaling in a novelty stress murine model. *Biomed Res Int* **2013**, 792940 (2013).
24. Simmler, C. *et al.* Dynamic residual complexity of the isoliquiritigenin-liquiritigenin interconversion during bioassay. *J Agric Food Chem* **61**, 2146–2157 (2013).
25. Xiang, C. *et al.* From single compounds to herbal extract: a strategy to systematically characterize the metabolites of licorice in rats. *Drug Metab Dispos* **39**, 1597–1608 (2011).
26. Kido, T. *et al.* Effects of rikkunshi-to, a traditional Japanese medicine, on the delay of gastric emptying induced by N(G)-nitro-L-arginine. *J Pharmacol Sci* **98**, 161–167 (2005).
27. Heisler, L. K., Zhou, L., Bajwa, P., Hsu, J. & Tecott, L. H. Serotonin 5-HT(2C) receptors regulate anxiety-like behavior. *Genes Brain Behav* **6**, 491–496 (2007).
28. Hotta, M., Shibasaki, T., Arai, K. & Demura, H. Corticotropin-releasing factor receptor type 1 mediates emotional stress-induced inhibition of food intake and behavioral changes in rats. *Brain Res* **823**, 221–225 (1999).
29. Zorrilla, E. P., Tache, Y. & Koob, G. F. Nibbling at CRF receptor control of feeding and gastrocolonic motility. *Trends Pharmacol Sci* **24**, 421–427 (2003).
30. Yakabi, K. *et al.* Rikkunshito and 5-HT2C receptor antagonist improve cisplatin-induced anorexia via hypothalamic ghrelin interaction. *Regul Pept* **161**, 97–105 (2010).
31. Tabuchi, M., Imamura, S., Kawakami, Z., Ikarashi, Y. & Kase, Y. The blood-brain barrier permeability of 18beta-glycyrrhetic acid, a major metabolite of glycyrrhizin in Glycyrrhiza root, a constituent of the traditional Japanese medicine yokukansan. *Cell Mol Neurobiol* **32**, 1139–1146 (2012).
32. Singh, S. P., Wahajuddin, Tewari, D., Patel, K. & Jain, G. K. Permeability determination and pharmacokinetic study of nobiletin in rat plasma and brain by validated high-performance liquid chromatography method. *Fitoterapia* **82**, 1206–1214 (2011).
33. Saigusa, D. *et al.* High-performance liquid chromatography with photodiode array detection for determination of nobiletin content in the brain and serum of mice administered the natural compound. *Anal Bioanal Chem* **400**, 3635–3641 (2011).
34. Li, T. *et al.* Simultaneous quantification of paeoniflorin, nobiletin, tangeretin, liquiritigenin, isoliquiritigenin, liquiritin and formononetin from Si-Ni-San extract in rat plasma and tissues by liquid chromatography-tandem mass spectrometry. *Biomed Chromatogr* **27**, 1041–1053 (2013).
35. Elahy, M. *et al.* Blood-brain barrier dysfunction developed during normal aging is associated with inflammation and loss of tight junctions but not with leukocyte recruitment. *Immun Ageing* **12**, 2 (2015).
36. Montagne, A. *et al.* Blood-brain barrier breakdown in the aging human hippocampus. *Neuron* **85**, 296–302 (2015).
37. Dulawa, S. C. & Hen, R. Recent advances in animal models of chronic antidepressant effects: the novelty-induced hypophagia test. *Neurosci Biobehav Rev* **29**, 771–783 (2005).
38. Hayashi, A., Suzuki, M., Sasamata, M. & Miyata, K. Agonist diversity in 5-HT(2C) receptor-mediated weight control in rats. *Psychopharmacology (Berl)* **178**, 241–249 (2005).
39. Kennett, G. A. *et al.* SB 242084, a selective and brain penetrant 5-HT2C receptor antagonist. *Neuropharmacology* **36**, 609–620 (1997).
40. Tsubouchi, H. *et al.* Rikkunshito ameliorates cachexia associated with bleomycin-induced lung fibrosis in mice by stimulating ghrelin secretion. *Nutr Res* **34**, 876–885 (2014).
41. Wang, L. *et al.* Patterns of Brain Activation and Meal Reduction Induced by Abdominal Surgery in Mice and Modulation by Rikkunshito. *PLoS One* **10**, e0139325 (2015).
42. Martinez, V. & Tache, Y. Role of CRF receptor 1 in central CRF-induced stimulation of colonic propulsion in rats. *Brain Res* **893**, 29–35 (2001).
43. Nakade, Y. *et al.* Restraint stress delays solid gastric emptying via a central CRF and peripheral sympathetic neuron in rats. *Am J Physiol Regul Integr Comp Physiol* **288**, R427–432 (2005).
44. Kask, A. & Schioth, H. B. Tonic inhibition of food intake during inactive phase is reversed by the injection of the melanocortin receptor antagonist into the paraventricular nucleus of the hypothalamus and central amygdala of the rat. *Brain Res* **887**, 460–464 (2000).
45. Haley, T. J. & McCormick, W. G. Pharmacological effects produced by intracerebral injection of drugs in the conscious mouse. *Br J Pharmacol Chemother* **12**, 12–15 (1957).
46. Chen, R., Lewis, K. A., Perrin, M. H. & Vale, W. W. Expression cloning of a human corticotropin-releasing-factor receptor. *Proc Natl Acad Sci USA* **90**, 8967–8971 (1993).
47. Chhajlani, V. Characterization of a putative alpha-MSH antagonist 153N-6 at melanocortin receptor subtypes by radioligand binding. *Peptides* **17**, 349–351 (1996).
48. Schioth, H. B. *et al.* Selectivity of cyclic [D-Nal7] and [D-Phe7] substituted MSH analogues for the melanocortin receptor subtypes. *Peptides* **18**, 1009–1013 (1997).

## Author Contributions

S.M., C.S., M.N., Y.M., C.Y. and T.H. contributed to the acquisition, analysis and interpretation of data and drafting of the manuscript. H.T. contributed to the conception and design of the study, analysis and interpretation of data and drafting of the manuscript.

## Additional Information

**Supplementary information** accompanies this paper at <http://www.nature.com/srep>

**Competing financial interests:** S.M., C.S., M.N., Y.M., C.Y. and T.H. are employed by Tsumura & Co. H.T. received grant support from Tsumura & Co.

**How to cite this article:** Mogami, S. *et al.* CRF receptor 1 antagonism and brain distribution of active components contribute to the ameliorative effect of rikkunshito on stress-induced anorexia. *Sci. Rep.* **6**, 27516; doi: 10.1038/srep27516 (2016).



This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>